Elevated Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$460K Buy
7,592
+4,185
+123% +$244K 0.12% 189
2025
Q4
$184K Buy
+3,407
New +$164K 0.04% 264

Other funds holding BMY

Elevated Capital Advisors's BMY Position: Q1 2026 in Review

Elevated Capital Advisors increased its Bristol-Myers Squibb (BMY) stake by 123% in Q1 2026, buying an estimated $244K and bringing the position to 7,592 shares worth $460K. The position accounts for 0.12% of the portfolio, ranked #189.

Elevated Capital Advisors first reported a position in BMY in Q4 2025 and has held it in 2 quarters since. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Elevated Capital Advisors held 7,592 shares of Bristol-Myers Squibb worth $460K as of Q1 2026.
  • Elevated Capital Advisors bought 4,185 Bristol-Myers Squibb shares in Q1 2026, an estimated $244K.
  • Bristol-Myers Squibb made up 0.12% of Elevated Capital Advisors's portfolio in Q1 2026, its #189 holding.
  • Elevated Capital Advisors first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 2 quarters since.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Elevated Capital Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.